(0.02%) 5 470.32 points
(0.15%) 39 172 points
(0.27%) 17 766 points
(0.01%) $80.84
(-5.04%) $2.62
(-0.87%) $2 310.60
(-0.22%) $28.81
(3.22%) $1 018.20
(0.33%) $0.936
(0.75%) $10.68
(0.50%) $0.792
(-0.28%) $87.24
-1.00% $ 11.70
Live Chart Being Loaded With Signals
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye...
Stats | |
---|---|
Volumen de hoy | 862 |
Volumen promedio | 38 046 |
Capitalización de mercado | 487.97M |
EPS | $-0.440 ( Q1 | 2024-05-08 ) |
Próxima fecha de ganancias | ( $-0.410 ) 2024-09-03 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
65.01 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0950 (0.81%) |
Oculis Holding AG Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Oculis Holding AG Finanzas
Annual | 2023 |
Ingresos: | $883 000 |
Beneficio Bruto: | $-28.36M (-3 212.23 %) |
EPS: | $-2.97 |
FY | 2023 |
Ingresos: | $883 000 |
Beneficio Bruto: | $-28.36M (-3 212.23 %) |
EPS: | $-2.97 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $-1.180 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company\'s lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico